Measurement of plasma von Willebrand factor cleaving protease in patients with varied thrombotic microangiopathy

Hisako Katagiri, Yohko Kawai, Noriko Sugizaki, Kazuo Sakai, Makoto Handa, Shinichiro Okamoto, Kiyoaki Watanabe

Research output: Contribution to journalArticle

Abstract

Thrombotic thrombocytopenic purpura(TTP) is a multisystem disorders characterized by thrombocytopenia, microangiopathic hemolytic anemia associated with red cell fragmentation, and neurological and renal symptoms. Plasma of patients with TTP has been shown to contain unusually large von Willebrand factor(vWF) multimers that may cause platelet agglutination in vivo. Recently, a metalloprotease responsible for cleavage of vWF multimers has been isolated from normal human plasma and was found to be deficient in some patients with TTP. We examined the activity of the vWF-cleaving protease(vWF-CP), by modified Furlan's method, in plasma from patients with a familial TTP, 3 acquired TTP, 4 thrombotic microangiopathy(TMA) and 2 veno-occlusive disease(VOD) associated after allo-BMT. Diluted plasma samples of patients were incubated with protease-free vWF purified from normal human plasma, in the presence of urea and barium ions. The extent of vWF degradation was assayed by electrophoresis in SDS-agarose gels and immunoblotting. Activity of vWF-CP from 12 normal plasma have been shown as 77-180%(average 115%), whereas, no vWF-CP(below 5%) was observed in plasma from familial TTP, before and after plasma exchange, although FFP infusion therapy has been effective for this patient to recover thrombocytopenia. In 3 acquired TTP, 2 patients showed lack of vWF-CP activity in plasma, and inhibitors against vWF-CP have been elucidated by plasma cross-mixing test. After extensive plasma exchange and FFP infusion followed by corticosteroid therapy, normal vWF-CP was recovered in plasma from 2 acquired TTP patients. Among BMT patients, plasma from 4 BMT-TMA showed normal vWF-CP activities as 55-111%, whereas plasma from 2 BMT-VOD revealed low vWF-CP activity, as 24% and 37%, respectively. Thus, measurement of vWF-CP is crucial to predict differentiation of primary forms of TMA to establish the pathogenesis in varied endothelial dysfunction.

Original languageEnglish
Pages (from-to)516-521
Number of pages6
JournalRinsho byori. The Japanese journal of clinical pathology
Volume51
Issue number6
Publication statusPublished - 2003 Jun

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Measurement of plasma von Willebrand factor cleaving protease in patients with varied thrombotic microangiopathy'. Together they form a unique fingerprint.

  • Cite this

    Katagiri, H., Kawai, Y., Sugizaki, N., Sakai, K., Handa, M., Okamoto, S., & Watanabe, K. (2003). Measurement of plasma von Willebrand factor cleaving protease in patients with varied thrombotic microangiopathy. Rinsho byori. The Japanese journal of clinical pathology, 51(6), 516-521.